An Exploratory proof-of Mechanism Study to Assess the Effect of Ruxolitinib on Tumor Infiltrating Myeloid Cells and Additional Immune Subsets in Prostate Cancer Patients
Phase of Trial: Phase II
Latest Information Update: 29 Jun 2019
Price : $35 *
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 02 Jan 2019 Planned End Date changed from 1 May 2019 to 31 Dec 2019.
- 02 Jan 2019 Planned primary completion date changed from 1 May 2019 to 31 Dec 2019.
- 31 Aug 2018 Biomarkers information updated